Prospective Evaluation of SARS-CoV-2 Antibodies Levels in a Vaccinated Population of Valle de Aburra
NCT ID: NCT05172167
Last Updated: 2022-03-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2022-02-02
2022-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this study , the variation of the SARS-Cov-2 antibody levels in patients from Valle de Aburrá will be correlated according to the COVID-19 vaccine received.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rapid Screening Test for Covid-19 Antibodies in Healthcare Workers
NCT04525417
Study of the Kinetics of COVID-19 Antibodies for 24 Months in Patients With Confirmed SARS-CoV-2 Infection
NCT04750720
Immunity Against COVID-19 Vaccine in Healthcare Workers in Argentine
NCT04843917
Correlation Study of Isotype Switching and Neutralizing Capacity to the COVID-19 Variants Strain
NCT05087277
Immune Responses to COVID-19; Isolation of Neutralizing Antibodies for Therapeutics and Vaccine.
NCT04596098
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
During the study will be done an active search for SARS-CoV-2 infections in the vaccinated people cohort, and if it is posible to characterize the variant of SARS-CoV-2 in participants previously vaccinated against this pathogen.
The main objective of this study is to describe the pattern of antibodies blood test based in the type of vaccine and correlated the pattern of antibodies SARS-Cov-2 levels in a population of Valle de Aburrá.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Early vaccinated against COVID-19
80 subjects with less than 4 months after being fully vaccinated against COVID-19
Levels of IgG and IgM SARS-CoV-2 antibodies blood test.
0,1,2 months
RT-PCR SARS-CoV-2 nasopharyngeal swab
0,1,2 months
Late vaccinated against COVID-19
80 subjects with more than 4 months after being fully vaccinated against COVID-19
Levels of IgG and IgM SARS-CoV-2 antibodies blood test.
0,1,2 months
RT-PCR SARS-CoV-2 nasopharyngeal swab
0,1,2 months
COVID-19 infection
40 patients diagnostic of COVID-19
Levels of IgG and IgM SARS-CoV-2 antibodies blood test.
0,1,2 months
RT-PCR SARS-CoV-2 nasopharyngeal swab
0,1,2 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Levels of IgG and IgM SARS-CoV-2 antibodies blood test.
0,1,2 months
RT-PCR SARS-CoV-2 nasopharyngeal swab
0,1,2 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The vaccinated patients to be included must have received a complete vaccination scheme for COVID-19 according to the Ministerio de Salud y Protección Social de Colombia
* SARS-CoV-2 infection in the last 2 months, verified by rtPCR test
Exclusion Criteria
* Immunosuppressive treatments, chemotherapy or antiretroviral therapy
* Outpatient anticoagulant therapy
* For vaccinated people (groups 1 and 2): if have had COVID-19 infection in the last 6 months
18 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Laboratorio integrado de medicina especializada(LIME)
UNKNOWN
Proyecto de regalias BPIN 2020000100152
UNKNOWN
Universidad de Antioquia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Andres Felipe Zuluaga Salazar
Full profesor, senior researcher and head of the Department of Pharmacology and Toxicology in Antioquia University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andres F Zuluaga, MD, MSc, MeH
Role: PRINCIPAL_INVESTIGATOR
Universidad de Antioquia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Laboratorio Integrado de Medicina Especializada
Medellín, Antioquia, Colombia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Andres F Zuluaga
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LIME-21-P-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.